NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, Price Target & More

Get Started

$88.28 -0.18 (-0.20 %)

(As of 05/24/2018 04:00 PM ET)

Previous Close$88.46

Today's Range$88.17 - $89.90

52-Week Range$75.81 - $100.03

Volume1.12 million shs

Average Volume1.35 million shs

Market Capitalization$15.48 billion

P/E Ratio-131.79

Dividend YieldN/A

Beta1.68

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:BMRN

CUSIP09061G10

Webwww.bmrn.com

Phone415-506-6700

Debt

Debt-to-Equity Ratio0.29

Current Ratio2.90

Quick Ratio2.29

Price-To-Earnings

Trailing P/E Ratio-131.79

Forward P/E Ratio-735.67

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.31 billion

Price / Sales11.88

Cash FlowN/A

Price / CashN/A

Book Value$15.88 per share

Price / Book5.56

Profitability

EPS (Most Recent Fiscal Year)($0.67)

Net Income$-117,040,000.00

Net Margins-10.48%

Return on Equity-3.01%

Return on Assets-1.89%

Miscellaneous

Employees2,581

Outstanding Shares176,710,000

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical (NASDAQ:BMRN) issued its quarterly earnings data on Wednesday, April, 25th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.08. The biotechnology company had revenue of $373.45 million for the quarter, compared to analysts' expectations of $348.73 million. BioMarin Pharmaceutical had a negative return on equity of 3.01% and a negative net margin of 10.48%. The company's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period last year, the business earned $0.20 earnings per share. View BioMarin Pharmaceutical's Earnings History.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for BioMarin Pharmaceutical.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $0.57-0.79 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.70. The company issued revenue guidance of $1.47-1.53 billion, compared to the consensus revenue estimate of $1.49 billion.

What price target have analysts set for BMRN?

20 analysts have issued twelve-month price targets for BioMarin Pharmaceutical's stock. Their forecasts range from $92.00 to $145.00. On average, they anticipate BioMarin Pharmaceutical's stock price to reach $112.1579 in the next year. View Analyst Ratings for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

1. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, backed by strong underlying patient demand trends. BioMarin expects sustained growth in both the drugs. Brineura’s earlier-than-expected approval was also a huge boost for BioMarin. Its impressive rare-disease pipeline is also progressing well with approval for pegvaliase expected in 2018. However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due to infrequent ordering patterns from some countries, mainly Brazil. The stock has also underperformed the industry in the past year. Earnings estimates have increased ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters." (4/25/2018)
2. JPMorgan Chase & Co. analysts commented, "BMRN’s 4Q print was largely in-line; the company also provided 2018 guidance that bracketed consensus revenue expectations. There was some incremental color on regulatory (pegvaliase) and commercial (Brineura/pegvaliase) progress / expectations for emerging products. Importantly, the pipeline continues on track, and 2019 looks to be a critical year on that front. We anticipate interest in BMRN will increase materially as we eventually get closer to the pivotal data for val rox and vosoritide. Reiterate OW." (2/25/2018)
3. Cowen Inc analysts commented, "New data include 52 wk follow-up on all patients at BMN270’s 6e13 vg/kg dose, and." (7/11/2017)

Who are some of BioMarin Pharmaceutical's key competitors?

Some companies that are related to BioMarin Pharmaceutical include Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), Grifols (GRFS), UCB (UCBJF) and Ono Pharmaceutical (OPHLF).

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:

Mr. Jean-Jacques Bienaimé, Chairman & CEO (Age 65)
Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 59)
Dr. Robert A. Baffi Ph.D., MBA, Exec. VP of Technical Operations (Age 63)
Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 56)
Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 60)

Has BioMarin Pharmaceutical been receiving favorable news coverage?

News headlines about BMRN stock have been trending somewhat positive on Thursday, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a news sentiment score of 0.06 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.73 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include PRIMECAP MANAGEMENT COMPANY (5.86%), Palo Alto Investors LP (1.44%), Manning & Napier Group LLC (1.08%), USS Investment Management Ltd (0.76%), OppenheimerFunds Inc. (0.71%) and Thrivent Financial for Lutherans (0.69%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

Which institutional investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Symphony Asset Management LLC, Point72 Asset Management L.P., Eaton Vance Management, TCW Group Inc., Swiss National Bank, American Century Companies Inc. and Element Capital Management LLC. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

Which institutional investors are buying BioMarin Pharmaceutical stock?

BMRN stock was bought by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, USS Investment Management Ltd, State of Wisconsin Investment Board, Prosight Management LP, Employees Retirement System of Texas, Palo Alto Investors LP, Bedell Frazier Investment Counseling LLC and Eagle Asset Management Inc.. View Insider Buying and Selling for BioMarin Pharmaceutical.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $88.28.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $15.48 billion and generates $1.31 billion in revenue each year. The biotechnology company earns $-117,040,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. BioMarin Pharmaceutical employs 2,581 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]

MarketBeat Community Rating for BioMarin Pharmaceutical (BMRN)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		958 (Vote Outperform)
Underperform Votes:		478 (Vote Underperform)
Total Votes:		1,436

MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

20 Wall Street analysts have issued ratings and price targets for BioMarin Pharmaceutical in the last 12 months. Their average twelve-month price target is $112.1579, suggesting that the stock has a possible upside of 27.05%. The high price target for BMRN is $145.00 and the low price target for BMRN is $92.00. There are currently 4 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.85	2.84	2.76	2.70
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 15 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 14 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$112.1579	$113.8421	$112.60	$112.5909
Price Target Upside:	27.05% upside	42.98% upside	34.05% upside	38.30% upside

BioMarin Pharmaceutical (NASDAQ:BMRN) Consensus Price Target History

Price Target History for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/16/2018	Canaccord Genuity	Initiated Coverage	Buy	$101.00	Low
5/15/2018	Wedbush	Reiterated Rating	Outperform	$112.00	Low
5/7/2018	Leerink Swann	Boost Price Target	Outperform	$132.00 ➝ $145.00	Medium
4/30/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$112.00 ➝ $113.00	High
4/30/2018	Sanford C. Bernstein	Lower Price Target	Market Perform	$97.00 ➝ $92.00	Medium
4/26/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$127.00	Medium
3/29/2018	Credit Suisse Group	Reiterated Rating	Buy	$116.00	Medium
2/27/2018	Royal Bank of Canada	Reiterated Rating	Hold	$94.00	Medium
2/23/2018	Stifel Nicolaus	Lower Price Target	Buy ➝ Buy	$105.00 ➝ $102.00	High
2/23/2018	BMO Capital Markets	Reiterated Rating	Outperform ➝ Outperform	$119.00 ➝ $125.00	High
2/23/2018	Deutsche Bank	Set Price Target	Buy ➝ Buy	$119.00 ➝ $124.00	High
1/18/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$114.00	Low
12/15/2017	Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy		High
12/11/2017	SunTrust Banks	Boost Price Target	Buy	$130.00	High
9/26/2017	Jefferies Group	Reiterated Rating	Buy	$116.00	Low
8/31/2017	Citigroup	Initiated Coverage	Buy ➝ Buy	$98.00	Medium
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$100.00	High
8/4/2017	Cowen	Reiterated Rating	Buy		Low
8/3/2017	UBS	Reiterated Rating	Neutral	$92.00 ➝ $93.00	Low
7/22/2017	Barclays	Reiterated Rating	Equal Weight	$105.00 ➝ $100.00	Low
3/1/2017	Instinet	Initiated Coverage	Neutral ➝ Neutral	$93.00	N/A
3/1/2017	Nomura	Initiated Coverage	Neutral		N/A
2/10/2017	Gabelli	Reiterated Rating	Buy		N/A
1/9/2017	Robert W. Baird	Set Price Target	Buy	$115.00	N/A
7/28/2016	William Blair	Set Price Target	Buy	$116.00	N/A
6/20/2016	Oppenheimer	Reiterated Rating	Market Perform	$99.00	N/A

(Data available from 5/24/2016 forward)

BioMarin Pharmaceutical (NASDAQ:BMRN) Earnings History and Estimates Chart

Earnings by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.59)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	($0.26)	$0.17	($0.11)
Q2 2018	3	($0.19)	($0.16)	($0.18)
Q3 2018	4	($0.21)	($0.10)	($0.15)
Q4 2018	3	($0.20)	($0.04)	($0.15)

BioMarin Pharmaceutical (NASDAQ BMRN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/31/2018		($0.22)					N/A
4/25/2018	Q1 2018	($0.17)	($0.25)	$348.73 million	$373.45 million	View	N/A
2/22/2018	Q4 2017	($0.24)	($0.30)	$346.24 million	$358.31 million	View	N/A
10/26/2017	Q3 2017	($0.13)	($0.07)	$347.38 million	$334.18 million	View	N/A
8/2/2017	Q2 2017	($0.22)	($0.21)	$311.41 million	$317.50 million	View	Listen
5/4/2017	Q1 2017	($0.30)	$0.03	$292.58 million	$303.70 million	View	Listen
2/23/2017	Q416	($0.38)	($0.53)	$296.54 million	$300.00 million	View	N/A
10/27/2016	Q316	($0.39)	($0.13)	$289.70 million	$279.90 million	View	Listen
8/4/2016	Q216	($0.52)	($2.61)	$278.75 million	$300.10 million	View	N/A
4/28/2016	Q116	($0.85)	($0.53)	$240.21 million	$236.70 million	View	Listen
2/25/2016	Q415	$0.67	$0.39	$224.14 million	$227.90 million	View	Listen
10/29/2015	Q315	($0.65)	($0.60)	$216.32 million	$208.90 million	View	Listen
8/3/2015	Q215	($0.53)	($0.22)	$218.16 million	$250.50 million	View	N/A
4/30/2015	Q1	($0.53)	($0.25)	$204.58 million	$203.26 million	View	N/A
2/25/2015	Q414	($0.59)	($0.30)	$189.01 million	$230.90 million	View	N/A
10/23/2014	Q314	($0.22)	($0.16)	$206.00 million	$176.80 million	View	Listen
7/30/2014	Q214	($0.42)	($0.19)	$159.70 million	$191.70 million	View	N/A
5/1/2014	Q1 2014	($0.50)	($0.27)	$145.16 million	$151.60 million	View	N/A
2/26/2014	Q413	($0.35)	($0.11)	$146.07 million	$146.90 million	View	N/A
10/24/2013	Q313	($0.30)	($0.38)	$140.00 million	$136.90 million	View	N/A
7/25/2013	Q2 2013	($0.29)	($0.16)	$134.33 million	$136.80 million	View	N/A
4/25/2013	Q1 2013	($0.30)	($0.31)	$131.35 million	$127.90 million	View	N/A
2/21/2013	Q4 2012	($0.22)	($0.43)	$129.70 million	$130.96 million	View	N/A
10/25/2012		($0.20)	($0.04)			View	N/A
8/1/2012		($0.19)	($0.27)			View	N/A
4/26/2012		($0.15)	($0.21)			View	N/A
2/16/2012		($0.10)	($0.23)			View	N/A
10/27/2011		($0.10)	($0.16)			View	N/A
7/28/2011		($0.09)	($0.05)			View	N/A
4/28/2011		($0.10)	$0.14			View	N/A
2/17/2011		($0.02)	($0.11)			View	N/A
10/28/2010	Q3 2010	($0.02)	($0.03)			View	N/A
8/2/2010	Q2 2010	$0.02	($0.01)			View	N/A
4/29/2010	Q1 2010		$0.01			View	N/A
2/23/2010	Q4 2009		$0.05			View	N/A
10/28/2009	Q3 2009		$0.06			View	N/A
4/30/2009	Q1 2009	($0.12)	($0.13)			View	N/A
2/18/2009	Q4 2008	$0.24	$0.24			View	N/A
10/28/2008	Q3 2008	$0.03	$0.01			View	N/A
8/5/2008	Q2 2008	$0.02	$0.04			View	N/A
4/29/2008	Q1 2008	($0.04)	$0.02			View	N/A
2/26/2008	Q4 2007	$0.04	$0.03			View	N/A

(Earnings results data provided by Zacks Investment Research)

BioMarin Pharmaceutical (NASDAQ:BMRN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

BioMarin Pharmaceutical (NASDAQ BMRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.90%

Insider Trading History for BioMarin Pharmaceutical (NASDAQ:BMRN)

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ BMRN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/17/2018	Jean Jacques Bienaime	CEO	Sell	18,750	$88.66	$1,662,375.00	309,350
5/15/2018	Jean Jacques Bienaime	CEO	Sell	37,500	$88.75	$3,328,125.00	309,350
5/11/2018	Jean Jacques Bienaime	CEO	Sell	18,750	$88.42	$1,657,875.00
5/10/2018	Brian Mueller	SVP	Sell	2,450	$89.50	$219,275.00	17,846
5/7/2018	Jeffrey Robert Ajer	EVP	Sell	309	$85.96	$26,561.64	53,223
4/24/2018	Jean Jacques Bienaime	CEO	Sell	20,000	$82.43	$1,648,600.00	300,031
4/23/2018	Daniel K Spiegelman	CFO	Sell	11,059	$82.15	$908,496.85	62,543
4/20/2018	Jean Jacques Bienaime	CEO	Sell	10,000	$83.65	$836,500.00	300,031
4/17/2018	V Bryan Lawlis	Director	Sell	3,750	$85.00	$318,750.00	18,610
4/2/2018	Henry J Fuchs	Insider	Sell	10,000	$80.12	$801,200.00	160,026
4/2/2018	Jeffrey Robert Ajer	EVP	Sell	2,119	$80.12	$169,774.28	52,914
3/29/2018	Jeffrey Robert Ajer	EVP	Sell	1,537	$79.69	$122,483.53	55,033
3/23/2018	George Eric Davis	EVP	Sell	3,350	$81.35	$272,522.50	87,989
3/21/2018	Jeffrey Robert Ajer	EVP	Sell	4,368	$83.90	$366,475.20	60,153
3/16/2018	George Eric Davis	EVP	Sell	3,818	$83.88	$320,253.84	94,634
3/15/2018	Jean Jacques Bienaime	CEO	Sell	15,000	$84.73	$1,270,950.00	279,674
3/9/2018	Jeffrey Robert Ajer	EVP	Sell	2,972	$82.39	$244,863.08	55,332
3/5/2018	George Eric Davis	EVP	Sell	2,105	$79.04	$166,379.20	90,089
2/15/2018	Jean Jacques Bienaime	CEO	Sell	10,000	$84.63	$846,300.00
2/1/2018	George Eric Davis	EVP	Sell	30,000	$90.66	$2,719,800.00	112,942
1/5/2018	Jean Jacques Bienaime	CEO	Sell	10,000	$90.32	$903,200.00	235,894
1/2/2018	Henry J. Fuchs	Insider	Sell	15,000	$89.23	$1,338,450.00
1/2/2018	V Bryan Lawlis	Director	Sell	3,750	$88.84	$333,150.00
12/29/2017	Jean Jacques Bienaime	CEO	Sell	20,000	$89.75	$1,795,000.00
12/29/2017	Jean Jacques Bienaime	CEO	Sell	10,000	$89.61	$896,100.00	226,494
12/14/2017	Elaine J Heron	Director	Sell	800	$88.90	$71,120.00	38,385
11/30/2017	George Eric Davis	EVP	Sell	1,200	$85.64	$102,768.00
9/28/2017	Robert Baffi	EVP	Sell	18,415	$92.43	$1,702,098.45	129,083
9/22/2017	Jeffrey Robert Ajer	EVP	Sell	3,521	$95.00	$334,495.00	49,299
9/15/2017	Henry J Fuchs	Insider	Sell	15,000	$90.50	$1,357,500.00	141,422
9/15/2017	V Bryan Lawlis	Director	Sell	3,750	$91.26	$342,225.00	19,660
6/23/2017	George Eric Davis	EVP	Sell	9,844	$96.60	$950,930.40	93,425
6/22/2017	Brian Mueller	SVP	Sell	2,671	$100.00	$267,100.00	15,556
6/19/2017	Henry J Fuchs	Insider	Sell	15,000	$90.00	$1,350,000.00	141,422
6/16/2017	V Bryan Lawlis	Director	Sell	3,750	$90.00	$337,500.00	19,660
6/7/2017	Jeffrey Robert Ajer	EVP	Sell	1,004	$89.61	$89,968.44	47,944
6/5/2017	George Eric Davis	EVP	Sell	9,471	$91.04	$862,239.84	74,342
6/5/2017	Jean Jacques Bienaime	CEO	Sell	10,000	$90.13	$901,300.00	238,564
5/24/2017	Jean Jacques Bienaime	CEO	Sell	5,000	$88.38	$441,900.00	238,564
5/17/2017	Jean Jacques Bienaime	CEO	Sell	5,000	$91.73	$458,650.00	238,564
5/8/2017	Brian Mueller	SVP	Sell	7,482	$91.87	$687,371.34	18,350
5/8/2017	Jean Jacques Bienaime	CEO	Sell	10,000	$96.09	$960,900.00	238,496
5/5/2017	George Eric Davis	EVP	Sell	2,500	$100.34	$250,850.00	85,251
5/2/2017	Jeffrey Robert Ajer	EVP	Sell	302	$96.74	$29,215.48	51,834
4/27/2017	Jean Jacques Bienaime	CEO	Sell	5,000	$95.72	$478,600.00	243,194
4/25/2017	Jean Jacques Bienaime	CEO	Sell	5,000	$94.00	$470,000.00	243,194
3/29/2017	Jeffrey Robert Ajer	EVP	Sell	3,890	$89.15	$346,793.50	51,532
3/16/2017	Daniel K Spiegelman	CFO	Sell	1,989	$91.96	$182,908.44	16,460
3/16/2017	George Eric Davis	EVP	Sell	2,238	$91.96	$205,806.48	75,967
3/16/2017	Jean Jacques Bienaime	CEO	Sell	10,000	$91.69	$916,900.00	211,364
3/10/2017	Jean Jacques Bienaime	CEO	Sell	11,000	$90.59	$996,490.00	212,364
3/7/2017	Jeffrey Robert Ajer	EVP	Sell	5,000	$90.56	$452,800.00	46,510
3/6/2017	Daniel K Spiegelman	CFO	Sell	2,303	$93.32	$214,915.96	20,761
3/6/2017	George Eric Davis	EVP	Sell	1,498	$93.32	$139,793.36	78,962
3/1/2017	Daniel K Spiegelman	CFO	Sell	35,000	$94.07	$3,292,450.00	60,347
3/1/2017	V Bryan Lawlis	Director	Sell	7,500	$95.00	$712,500.00	21,360
2/24/2017	Henry J Fuchs	Insider	Sell	15,000	$87.99	$1,319,850.00	128,442
1/26/2017	Jean Jacques Bienaime	CEO	Sell	10,000	$84.22	$842,200.00	175,682
1/11/2017	Jean Jacques Bienaime	CEO	Sell	8,000	$90.58	$724,640.00	174,682
1/9/2017	Daniel K Spiegelman	CFO	Sell	5,000	$90.00	$450,000.00	18,100
1/9/2017	Jean Jacques Bienaime	CEO	Sell	8,000	$88.49	$707,920.00	174,682
12/30/2016	Jean Jacques Bienaime	CEO	Sell	8,000	$83.60	$668,800.00	174,682
11/22/2016	Jean Jacques Bienaime	CEO	Sell	69,743	$85.69	$5,976,277.67
11/21/2016	Jean Jacques Bienaime	CEO	Sell	69,744	$87.56	$6,106,784.64
11/8/2016	Jean Jacques Bienaime	CEO	Sell	140,000	$82.67	$11,573,800.00	393,368
11/7/2016	Jean Jacques Bienaime	CEO	Sell	70,000	$82.52	$5,776,400.00	393,368
10/28/2016	Jean Jacques Bienaime	CEO	Sell	120,000	$81.30	$9,756,000.00	383,368
10/17/2016	Jean Jacques Bienaime	CEO	Sell	41,666	$84.39	$3,516,193.74	365,034
10/14/2016	Jean Jacques Bienaime	CEO	Sell	64,125	$86.96	$5,576,310.00	378,184
9/29/2016	Jean Jacques Bienaime	CEO	Sell	53,125	$93.65	$4,975,156.25	431,709
9/27/2016	Jeffrey Robert Ajer	EVP	Sell	18,467	$95.61	$1,765,629.87	41,342
9/16/2016	Jean Jacques Bienaime	CEO	Sell	137,368	$95.34	$13,096,665.12	421,161
8/26/2016	Henry J Fuchs	EVP	Sell	15,000	$95.06	$1,425,900.00	128,878
8/16/2016	Jean Jacques Bienaime	CEO	Sell	41,666	$91.49	$3,812,022.34	420,250
8/1/2016	Brian Mueller	VP	Sell	287	$100.00	$28,700.00	14,260
8/1/2016	Daniel K Spiegelman	CFO	Sell	4,000	$99.33	$397,320.00	42,944
8/1/2016	George Eric Davis	EVP	Sell	2,167	$100.00	$216,700.00	71,158
7/27/2016	V Bryan Lawlis	Director	Sell	1,100	$95.39	$104,929.00	14,960
7/22/2016	V Bryan Lawlis	Director	Sell	6,400	$95.01	$608,064.00	20,260
7/18/2016	Jean Jacques Bienaime	CEO	Sell	41,666	$92.72	$3,863,271.52	420,250
7/7/2016	George Eric Davis	EVP	Sell	2,167	$90.00	$195,030.00	72,836
6/20/2016	V Bryan Lawlis	Director	Sell	550	$82.77	$45,523.50	13,860
6/16/2016	Jean Jacques Bienaime	CEO	Sell	41,666	$80.55	$3,356,196.30	420,250
6/6/2016	Daniel K Spiegelman	CFO	Sell	1,649	$89.14	$146,991.86	46,944
5/31/2016	Daniel K Spiegelman	CFO	Sell	20,841	$89.88	$1,873,189.08	71,235
5/26/2016	Henry J Fuchs	EVP	Sell	15,000	$87.81	$1,317,150.00	130,914
5/23/2016	Daniel K Spiegelman	CFO	Sell	3,769	$87.07	$328,166.83	58,644
5/18/2016	Robert Baffi	EVP	Sell	5,000	$87.05	$435,250.00	130,386
5/10/2016	George Eric Davis	EVP	Sell	14,658	$85.11	$1,247,542.38	91,894
5/5/2016	Jean Jacques Bienaime	CEO	Sell	50,000	$80.15	$4,007,500.00	390,156
5/3/2016	Jeffrey Robert Ajer	EVP	Sell	415	$86.03	$35,702.45	63,487
5/2/2016	Jean Jacques Bienaime	CEO	Sell	36,500	$85.01	$3,102,865.00	395,635
3/14/2016	George Eric Davis	EVP	Sell	1,996	$86.21	$172,075.16	76,190
3/4/2016	Jeffrey Robert Ajer	SVP	Sell	1,255	$88.42	$110,967.10	48,137
3/2/2016	Daniel K Spiegelman	CFO	Sell	4,623	$86.12	$398,132.76	54,311
3/1/2016	Jean Jacques Bienaime	CEO	Sell	10,000	$84.28	$842,800.00	350,500
2/22/2016	Michael G Grey	Director	Sell	7,500	$80.00	$600,000.00	33,750
12/16/2015	George Eric Davis	SVP	Sell	1,362	$100.00	$136,200.00	66,156
11/30/2015	Jean Jacques Bienaime	CEO	Sell	1,000	$94.74	$94,740.00	228,754
11/16/2015	Daniel K. Spiegelman	CFO	Sell	20,000	$104.30	$2,086,000.00	28,229
11/16/2015	V Bryan Lawlis	Director	Sell	8,550	$106.90	$913,995.00	11,850
10/15/2015	Jean Jacques Bienaime	CEO	Sell	1,000	$108.24	$108,240.00	228,754
9/14/2015	Jean Jacques Bienaime	CEO	Sell	1,000	$131.43	$131,430.00	228,754
7/20/2015	Jeffrey Robert Ajer	SVP	Sell	3,000	$150.00	$450,000.00
7/7/2015	Jean Jacques Bienaime	CEO	Sell	1,500	$139.07	$208,605.00
6/5/2015	Daniel K Spiegelman	CFO	Sell	1,649	$122.30	$201,672.70
6/5/2015	Henry J Fuchs	EVP	Sell	1,864	$122.32	$228,004.48
6/4/2015	Jeffrey Robert Ajer	SVP	Sell	1,362	$122.35	$166,640.70
6/1/2015	Daniel K Spiegelman	CFO	Sell	5,523	$124.73	$688,883.79
6/1/2015	Jeffrey Robert Ajer	SVP	Sell	377	$123.76	$46,657.52
5/29/2015	Daniel K Spiegelman	CFO	Sell	1,578	$126.15	$199,064.70
5/26/2015	Jeffrey Robert Ajer	SVP	Sell	1,625	$126.55	$205,643.75
5/18/2015	Daniel K Spiegelman	CFO	Sell	2,059	$124.77	$256,901.43
5/18/2015	George Eric Davis	SVP	Sell	2,558	$125.26	$320,415.08
5/18/2015	Henry J Fuchs	EVP	Sell	1,864	$124.78	$232,589.92
5/13/2015	Henry J Fuchs	EVP	Sell	1,434	$121.37	$174,044.58
5/11/2015	Henry J Fuchs	EVP	Sell	2,869	$121.64	$348,985.16
3/17/2015	Jean Jacques Bienaime	CEO	Sell	2,000	$124.17	$248,340.00
3/16/2015	Henry J Fuchs	EVP	Sell	41,315	$123.57	$5,105,294.55
3/16/2015	Jean Jacques Bienaime	CEO	Sell	1,000	$123.48	$123,480.00
3/10/2015	Jean Jacques Bienaime	CEO	Sell	21,021	$112.39	$2,362,550.19
3/9/2015	Jean Jacques Bienaime	CEO	Sell	19,000	$112.13	$2,130,470.00
3/5/2015	Jean Jacques Bienaime	CEO	Sell	10,000	$113.70	$1,137,000.00
3/5/2015	Robert Baffi	EVP	Sell	14,051	$116.37	$1,635,114.87
3/4/2015	Jean Jacques Bienaime	CEO	Sell	13,916	$107.92	$1,501,814.72
3/3/2015	Jean Jacques Bienaime	CEO	Sell	5,000	$107.42	$537,100.00
3/2/2015	Daniel K Spiegelman	CFO	Sell	15,500	$107.00	$1,658,500.00
3/2/2015	George Eric Davis	SVP	Sell	23,000	$108.31	$2,491,130.00
3/2/2015	Jean Jacques Bienaime	CEO	Sell	5,000	$108.44	$542,200.00
1/9/2015	Jean Jacques Bienaime	CEO	Sell	2,000	$94.14	$188,280.00
12/24/2014	Jean Jacques Bienaime	CEO	Sell	5,000	$88.73	$443,650.00
12/10/2014	Jean Jacques Bienaime	CEO	Sell	2,000	$95.00	$190,000.00
12/4/2014	Alan Lewis	Director	Sell	7,500	$89.90	$674,250.00
12/2/2014	Brian Mueller	VP	Sell	11,950	$90.91	$1,086,374.50
11/25/2014	George Eric Davis	SVP	Sell	20,000	$89.75	$1,795,000.00
11/25/2014	Jean Jacques Bienaime	CEO	Sell	2,000	$90.00	$180,000.00
11/12/2014	Jean Jacques Bienaime	CEO	Sell	1,000	$81.51	$81,510.00
11/10/2014	Henry J Fuchs	EVP	Sell	20,000	$86.55	$1,731,000.00
11/10/2014	Jean Jacques Bienaime	CEO	Sell	4,000	$87.00	$348,000.00
11/3/2014	Jean Jacques Bienaime	CEO	Sell	3,000	$85.33	$255,990.00
11/3/2014	Jeffrey Robert Ajer	SVP	Sell	47	$83.54	$3,926.38
10/30/2014	Robert Baffi	EVP	Sell	75,425	$81.34	$6,135,069.50
10/24/2014	Jean Jacques Bienaime	CEO	Sell	2,000	$80.00	$160,000.00
9/19/2014	George Eric Davis	SVP	Sell	17,536	$69.75	$1,223,136.00
9/2/2014	Daniel K Spiegelman	CFO	Sell	16,000	$69.83	$1,117,280.00
8/20/2014	Jean Jacques Bienaime	CEO	Sell	5,000	$70.00	$350,000.00
8/5/2014	Henry J Fuchs	EVP	Sell	10,000	$65.00	$650,000.00
8/1/2014	Daniel K Spiegelman	CFO	Sell	2,229	$61.76	$137,663.04
7/2/2014	Daniel K Spiegelman	CFO	Sell	2,229	$64.00	$142,656.00
6/4/2014	Jean Jacques Bienaime	CEO	Sell	2,000	$61.20	$122,400.00
5/22/2014	Jean Jacques Bienaime	CEO	Sell	1,000	$56.88	$56,880.00	180,257
5/21/2014	Jean Jacques Bienaime	CEO	Sell	1,545	$56.19	$86,813.55	180,257
5/16/2014	Henry Fuchs	EVP	Sell	1,864	$56.86	$105,987.04	60,950
5/16/2014	Jeffrey Robert Ajer	SVP	Sell	1,004	$56.91	$57,137.64	20,980
5/16/2014	V Bryan Lawlis	Director	Sell	1,700	$56.87	$96,679.00	9,700
5/13/2014	Henry Fuchs	EVP	Sell	1,434	$58.23	$83,501.82	64,850
5/9/2014	Henry Fuchs	EVP	Sell	3,479	$57.91	$201,468.89	67,850
2/3/2014	Henry Fuchs	EVP	Sell	10,000	$67.70	$677,000.00	42,350
12/24/2013	Jean Jacques Bienaime	CEO	Sell	10,000	$68.71	$687,100.00
12/5/2013	Jean Jacques Bienaime	CEO	Sell	5,000	$69.70	$348,500.00
10/16/2013	Jean Jacques Bienaime	CEO	Sell	2,000	$67.73	$135,460.00
10/10/2013	Jean Jacques Bienaime	CEO	Sell	3,000	$66.76	$200,280.00
9/19/2013	Henry Fuchs	EVP	Sell	10,000	$80.19	$801,900.00	43,266
9/16/2013	Jean Jacques Bienaime	CEO	Sell	2,000	$73.08	$146,160.00
9/9/2013	Robert Baffi	EVP	Sell	20,000	$73.00	$1,460,000.00
9/5/2013	Henry J Fuchs	EVP	Sell	10,000	$70.00	$700,000.00
9/4/2013	Daniel K Spiegelman	CFO	Sell	9,000	$69.00	$621,000.00
8/15/2013	Jean Jacques Bienaime	CEO	Sell	1,000	$64.36	$64,360.00
7/1/2013	Daniel K Spiegelman	CFO	Sell	4,066	$59.78	$243,065.48
7/1/2013	Henry J Fuchs	EVP	Sell	10,000	$60.00	$600,000.00
6/3/2013	Henry J Fuchs	EVP	Sell	1,098	$58.32	$64,035.36
5/23/2013	Henry J Fuchs	EVP	Sell	20,609	$66.29	$1,366,170.61
5/22/2013	Mark Wood	VP	Sell	3,103	$67.12	$208,273.36
5/21/2013	Jean Jacques Bienaime	CEO	Sell	2,000	$64.14	$128,280.00
5/16/2013	Jean Jacques Bienaime	CEO	Sell	12,000	$67.90	$814,800.00
5/14/2013	Brian Mueller	VP	Sell	4,947	$70.35	$348,021.45
5/14/2013	George Eric Davis	SVP	Sell	20,000	$70.34	$1,406,800.00
5/14/2013	Jean Jacques Bienaime	CEO	Sell	15,000	$70.17	$1,052,550.00
5/13/2013	Jean Jacques Bienaime	CEO	Sell	15,800	$68.77	$1,086,566.00
5/13/2013	Jeffrey Robert Ajer	SVP	Sell	1,248	$69.26	$86,436.48
5/8/2013	Jean Jacques Bienaime	CEO	Sell	4,000	$65.87	$263,480.00
5/2/2013	Jean Jacques Bienaime	CEO	Sell	3,000	$64.99	$194,970.00
4/10/2013	Robert Baffi	EVP	Sell	20,000	$64.00	$1,280,000.00
3/22/2013	Mark Wood	VP	Sell	3,103	$60.21	$186,831.63
3/4/2013	George Eric Davis	SVP	Sell	4,000	$60.18	$240,720.00
2/22/2013	Mark Wood	VP	Sell	3,103	$55.22	$171,347.66
2/4/2013	Jean Jacques Bienaime	CEO	Sell	2,000	$55.77	$111,540.00
12/27/2012	Jean Jacques Bienaime	CEO	Sell	17,000	$48.37	$822,290.00
11/12/2012	George Eric Davis	SVP	Sell	99,075	$48.45	$4,800,183.75
9/4/2012	Henry J Fuchs	EVP	Sell	5,000	$37.76	$188,800.00
8/22/2012	Mark Wood	VP	Sell	2,665	$37.93	$101,083.45

(Data available from 1/1/2013 forward)

BioMarin Pharmaceutical (NASDAQ BMRN) News Headlines

Source:

Date	Headline
	BioMarin Pharma (BMRN) Should Not Be Selling Off on Heme Data - Citi www.streetinsider.com - May 24 at 4:28 PM
	BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene ... www.prnewswire.com - May 24 at 4:28 PM
	A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker finance.yahoo.com - May 23 at 4:25 PM
	The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work finance.yahoo.com - May 19 at 9:31 AM
	BioMarin Pharmaceutical (BMRN) CEO Sells $1,662,375.00 in Stock www.americanbankingnews.com - May 18 at 7:29 PM
	Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list finance.yahoo.com - May 17 at 4:25 PM
	BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress finance.yahoo.com - May 17 at 4:25 PM
	BioMarin Pharma (BMRN) Reports First Patient Dosed in Phase 1/2 Study ... www.streetinsider.com - May 17 at 9:38 AM
	$356.89 Million in Sales Expected for BioMarin Pharmaceutical (BMRN) This Quarter www.americanbankingnews.com - May 17 at 2:19 AM
	Jean Jacques Bienaime Sells 37,500 Shares of BioMarin Pharmaceutical (BMRN) Stock www.americanbankingnews.com - May 16 at 7:16 PM
	Canaccord Genuity Initiates Coverage on BioMarin Pharmaceutical (BMRN) www.americanbankingnews.com - May 16 at 1:49 PM
	BioMarin Begins Mid Stage Study on Gene Therapy Candidate www.zacks.com - May 16 at 10:01 AM
	Brokerages Expect BioMarin Pharmaceutical (BMRN) to Post $0.14 Earnings Per Share www.americanbankingnews.com - May 15 at 7:14 PM
	BioMarin Pharmaceutical (BMRN) Given "Outperform" Rating at Wedbush www.americanbankingnews.com - May 15 at 1:56 PM
	BioMarin starts Phase 1/2 study of gene therapy for hemophilia A subgroup seekingalpha.com - May 15 at 10:04 AM
	BioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy in Severe Hemophilia A Patients with Pre-existing AAV5 Antibodies finance.yahoo.com - May 15 at 10:04 AM
	Insider Selling: BioMarin Pharmaceutical (BMRN) SVP Sells 2,450 Shares of Stock www.americanbankingnews.com - May 14 at 10:12 PM
	BioMarin Pharmaceutical (BMRN) CEO Jean Jacques Bienaime Sells 18,750 Shares www.americanbankingnews.com - May 14 at 10:12 PM
	BioMarin Pharmaceutical Is Doing Better but Patience Is Needed finance.yahoo.com - May 11 at 4:34 PM
	Cramer says it's 'very hard to put a price on' lifesaving... finance.yahoo.com - May 11 at 4:34 PM
	ValuEngine Upgrades BioMarin Pharmaceutical (BMRN) to "Hold" www.americanbankingnews.com - May 11 at 11:12 AM
	What to Expect From Trump's Speech on Drug Prices on Friday www.thestreet.com - May 10 at 4:26 PM
	Jeffrey Robert Ajer Sells 309 Shares of BioMarin Pharmaceutical (BMRN) Stock www.americanbankingnews.com - May 9 at 8:28 PM
	BioMarin Pharmaceutical (BMRN) Upgraded to "Hold" at BidaskClub www.americanbankingnews.com - May 8 at 11:02 AM
	BMRN Makes Bullish Cross Above Critical Moving Average www.nasdaq.com - May 8 at 9:31 AM
	First US drug priced at more than $1 million may be on the horizon finance.yahoo.com - May 7 at 4:28 PM
	Why Hemophilia Patients Could Pay $1.5 Million For Gene Therapy finance.yahoo.com - May 7 at 4:28 PM
	BioMarin Pharmaceutical (BMRN) PT Raised to $145.00 at Leerink Swann www.americanbankingnews.com - May 7 at 2:58 PM
	The Top Biopharma Catalysts Coming in May www.msn.com - May 5 at 9:41 AM
	BioMarin Named To Forbes List Of America's Best Mid-size Employers finance.yahoo.com - May 1 at 4:22 PM
	BioMarin Pharmaceutical (BMRN) Lifted to Sell at BidaskClub www.americanbankingnews.com - May 1 at 9:41 AM
	BioMarin Pharmaceutical (BMRN) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 30 at 3:42 PM
	BioMarin Pharmaceutical (BMRN) Price Target Raised to $113.00 at Morgan Stanley www.americanbankingnews.com - April 30 at 11:41 AM
	BioMarin Pharmaceutical (BMRN) Earns Outperform Rating from Wedbush www.americanbankingnews.com - April 30 at 9:26 AM
	Sanford C. Bernstein Reiterates "Market Perform" Rating for BioMarin Pharmaceutical (BMRN) www.americanbankingnews.com - April 30 at 8:57 AM
	BioMarin Pharmaceutical (BMRN) Expected to Announce Quarterly Sales of $364.57 Million www.americanbankingnews.com - April 30 at 4:51 AM
	BioMarin Cruises While It Waits on Seventh Approval finance.yahoo.com - April 28 at 10:07 AM
	BioMarin Pharmaceutical (BMRN) Expected to Announce Earnings of $0.16 Per Share www.americanbankingnews.com - April 28 at 5:14 AM
	How Did BioMarin Pharmaceutical Perform in 1Q18? finance.yahoo.com - April 27 at 4:16 PM
	How Did Vertex Pharmaceuticals Perform in 1Q18? finance.yahoo.com - April 27 at 4:16 PM
	BioMarin Pharmaceutical (BMRN) PT Set at $127.00 by JPMorgan Chase www.americanbankingnews.com - April 27 at 10:30 AM
	Alexion Saw 48% Rise in Diluted Earnings per Share in 1Q18 finance.yahoo.com - April 27 at 10:07 AM
	BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat finance.yahoo.com - April 26 at 4:23 PM
	BioMarin Pharmaceutical misses by $0.08, beats on revenue seekingalpha.com - April 26 at 9:30 AM
	Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings www.msn.com - April 26 at 9:30 AM
	BioMarin Pharmaceutical (BMRN) Q1 2018 Results - Earnings Call Transcript seekingalpha.com - April 26 at 9:30 AM
	BioMarin: 1Q Earnings Snapshot finance.yahoo.com - April 26 at 9:30 AM
	BioMarin Pharmaceutical (BMRN) CFO Daniel K. Spiegelman Sells 11,059 Shares www.americanbankingnews.com - April 25 at 10:16 PM
	Insider Selling: BioMarin Pharmaceutical (BMRN) CEO Sells 20,000 Shares of Stock www.americanbankingnews.com - April 25 at 10:16 PM
	BioMarin Pharmaceutical (BMRN) Issues Quarterly Earnings Results, Beats Expectations By $0.22 EPS www.americanbankingnews.com - April 25 at 8:40 PM

BioMarin Pharmaceutical (NASDAQ:BMRN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

BioMarin Pharmaceutical (NASDAQ:BMRN) Income Statement, Balance Sheet and Cash Flow Statement

BioMarin Pharmaceutical (NASDAQ BMRN) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff